Your browser doesn't support javascript.
loading
A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens.
Lee, Yi-Hsuan; Huang, Chung-Yen; Hsieh, Yu-Han; Yang, Chia-Hung; Hung, Yu-Ling; Chen, Yung-An; Lin, Yu-Chieh; Lin, Ching-Hung; Lee, Jih-Hsiang; Wang, Ming-Yang; Kuo, Wen-Hung; Lin, Yen-Yin; Lu, Yen-Shen.
Afiliação
  • Lee YH; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
  • Huang CY; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
  • Hsieh YH; JelloX Biotech Inc, Hsinchu, Taiwan.
  • Yang CH; JelloX Biotech Inc, Hsinchu, Taiwan.
  • Hung YL; JelloX Biotech Inc, Hsinchu, Taiwan.
  • Chen YA; JelloX Biotech Inc, Hsinchu, Taiwan.
  • Lin YC; JelloX Biotech Inc, Hsinchu, Taiwan.
  • Lin CH; Department of Medical Oncology, Cancer Center Branch, National Taiwan University Hospital, Taipei, Taiwan.
  • Lee JH; Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
  • Wang MY; Department of Oncology, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan.
  • Kuo WH; Department of Surgical Oncology, Cancer Center Branch, National Taiwan University Hospital, Taipei, Taiwan.
  • Lin YY; Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
  • Lu YS; JelloX Biotech Inc, Hsinchu, Taiwan.
BMC Cancer ; 24(1): 121, 2024 Jan 24.
Article em En | MEDLINE | ID: mdl-38267903
ABSTRACT

BACKGROUND:

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are the two most common immune checkpoints targeted in triple-negative breast cancer (BC). Refining patient selection for immunotherapy is non-trivial and finding an appropriate digital pathology framework for spatial analysis of theranostic biomarkers for PD-1/PD-L1 inhibitors remains an unmet clinical need.

METHODS:

We describe a novel computer-assisted tool for three-dimensional (3D) imaging of PD-L1 expression in immunofluorescence-stained and optically cleared BC specimens (n = 20). The proposed 3D framework appeared to be feasible and showed a high overall agreement with traditional, clinical-grade two-dimensional (2D) staining techniques. Additionally, the results obtained for automated immune cell detection and analysis of PD-L1 expression were satisfactory.

RESULTS:

The spatial distribution of PD-L1 expression was heterogeneous across various BC tissue layers in the 3D space. Notably, there were six cases (30%) wherein PD-L1 expression levels along different layers crossed the 1% threshold for admitting patients to PD-1/PD-L1 inhibitors. The average PD-L1 expression in 3D space was different from that of traditional immunohistochemistry (IHC) in eight cases (40%). Pending further standardization and optimization, we expect that our technology will become a valuable addition for assessing PD-L1 expression in patients with BC.

CONCLUSION:

Via a single round of immunofluorescence imaging, our approach may provide a considerable improvement in patient stratification for cancer immunotherapy as compared with standard techniques.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Limite: Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article